GARS1 and cancer: The relationship between the alterations of these cellular processes and cancer formation mechanisms described for other ARSs (Lee et al., 2006; Wang and Yang, 2020; Sung et al., 2022) indicates that Fraisinib’s anti-tumoral activity could depend on GARS1 targeting.